Literature DB >> 19023884

Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas.

Federica Barbagallo1, Maria P Paronetto, Renato Franco, Paolo Chieffi, Susanna Dolci, Andrew M Fry, Raffaele Geremia, Claudio Sette.   

Abstract

Protein kinases that regulate the centrosome cycle are often aberrantly controlled in neoplastic cells. Changes in their expression or activity can lead to perturbations in centrosome duplication, potentially leading to chromosome segregation errors and aneuploidy. Testicular germ cell tumours (TGCTs) are characterized by amplification of centrosomes through unknown mechanisms. Herein, we report that Nek2, a centrosomal kinase required for centrosome disjunction and formation of the mitotic spindle, is up-regulated in human testicular seminomas as compared to control testes or other types of testicular germ cell tumours. In addition, Nek2 activity is also increased in human seminomas, as demonstrated by immunokinase assays. Analysis by immunohistochemistry indicated that Nek2 is prevalently localized in the nucleus of neoplastic cells of primary human seminomas. Such nuclear localization and the up-regulation of Nek2 protein were also observed in the Tcam-2 seminoma cell line. We demonstrate that nuclear localization of Nek2 is a feature of the more undifferentiated germ cells of mouse testis and correlates with expression of the stemness markers OCT4 and PLZF. These studies suggest that up-regulation of Nek2 is a frequent event in human seminomas and that this may participate in the onset or progression of neoplastic transformation through deregulation of centrosome duplication and/or nuclear events in germ cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19023884     DOI: 10.1002/path.2471

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  28 in total

1.  Local depletion of DNA methylation identifies a repressive p53 regulatory region in the NEK2 promoter.

Authors:  Nancy H Nabilsi; Daniel J Ryder; Ashley C Peraza-Penton; Rosha Poudyal; David S Loose; Michael P Kladde
Journal:  J Biol Chem       Date:  2013-10-25       Impact factor: 5.157

2.  Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.

Authors:  Jia Wang; Peng Cheng; Marat S Pavlyukov; Hai Yu; Zhuo Zhang; Sung-Hak Kim; Mutsuko Minata; Ahmed Mohyeldin; Wanfu Xie; Dongquan Chen; Violaine Goidts; Brendan Frett; Wenhao Hu; Hongyu Li; Yong Jae Shin; Yeri Lee; Do-Hyun Nam; Harley I Kornblum; Maode Wang; Ichiro Nakano
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

3.  An up-date on epigenetic and molecular markers in testicular germ cell tumors.

Authors:  Paolo Chieffi
Journal:  Intractable Rare Dis Res       Date:  2017-11

Review 4.  Targeting NEK2 as a promising therapeutic approach for cancer treatment.

Authors:  Yanfen Fang; Xiongwen Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 5.  Recent advances in the biology of germ cell tumors: implications for the diagnosis and treatment.

Authors:  P Chieffi; S Chieffi; R Franco; A A Sinisi
Journal:  J Endocrinol Invest       Date:  2012-11-12       Impact factor: 4.256

6.  Irreversible Nek2 kinase inhibitors with cellular activity.

Authors:  Jeffrey C Henise; Jack Taunton
Journal:  J Med Chem       Date:  2011-05-31       Impact factor: 7.446

7.  New perspective on molecular markers as promising therapeutic targets in germ cell tumors.

Authors:  Paolo Chieffi
Journal:  Intractable Rare Dis Res       Date:  2016-05

8.  Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.

Authors:  Z Cierna; M Mego; V Miskovska; K Machalekova; M Chovanec; D Svetlovska; K Hainova; K Rejlekova; D Macak; S Spanik; D Ondrus; K Kajo; J Mardiak; P Babal
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976

9.  Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism.

Authors:  C-M Hu; J Zhu; X E Guo; W Chen; X-L Qiu; B Ngo; R Chien; Y V Wang; C Y Tsai; G Wu; Y Kim; R Lopez; A R Chamberlin; E Y-H P Lee; W-H Lee
Journal:  Oncogene       Date:  2014-03-24       Impact factor: 9.867

10.  Clinical significance and prognostic value of Nek2 protein expression in colon cancer.

Authors:  Lei Lu; Xiaofeng Zhai; Ronghua Yuan
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.